6.95
0.07 (1.02%)
| Previous Close | 6.88 |
| Open | 6.92 |
| Volume | 661,480 |
| Avg. Volume (3M) | 1,158,036 |
| Market Cap | 647,835,328 |
| Price / Earnings (Forward) | 54.05 |
| Price / Sales | 0.570 |
| Price / Book | 1.28 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Profit Margin | -12.20% |
| Operating Margin (TTM) | -14.80% |
| Diluted EPS (TTM) | -1.12 |
| Quarterly Revenue Growth (YOY) | -3.10% |
| Total Debt/Equity (MRQ) | 22.36% |
| Current Ratio (MRQ) | 1.90 |
| Operating Cash Flow (TTM) | -6.40 M |
| Levered Free Cash Flow (TTM) | 18.68 M |
| Return on Assets (TTM) | -5.26% |
| Return on Equity (TTM) | -13.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | Myriad Genetics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.30 |
|
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 2.77% |
| % Held by Institutions | 104.21% |
| 52 Weeks Range | ||
| Median | 8.50 (22.30%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 11 Nov 2025 | 8.50 (22.30%) | Buy | 6.68 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HAAS KEVIN RICHARD | 5.47 | - | 23,697 | 129,623 |
| MUZZEY DALE | 5.47 | - | 23,697 | 129,623 |
| VERRATTI MARK | 5.47 | - | 32,810 | 179,471 |
| WHEELER BENJAMIN RICHARD | 5.47 | - | 4,994 | 27,317 |
| Aggregate Net Quantity | 85,198 | |||
| Aggregate Net Value ($) | 466,033 | |||
| Aggregate Avg. Buy ($) | 5.47 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MUZZEY DALE | Officer | 02 Feb 2026 | Acquired (+) | 23,697 | 5.47 | 129,623 |
| HAAS KEVIN RICHARD | Officer | 02 Feb 2026 | Acquired (+) | 23,697 | 5.47 | 129,623 |
| WHEELER BENJAMIN RICHARD | Officer | 02 Feb 2026 | Acquired (+) | 4,994 | 5.47 | 27,317 |
| VERRATTI MARK | Officer | 02 Feb 2026 | Acquired (+) | 32,810 | 5.47 | 179,471 |
| Date | Type | Details |
|---|---|---|
| 27 Jan 2026 | Announcement | Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data |
| 12 Jan 2026 | Announcement | Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance |
| 05 Jan 2026 | Announcement | Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 09 Dec 2025 | Announcement | Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium |
| 25 Nov 2025 | Announcement | Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health |
| 11 Nov 2025 | Announcement | Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences |
| 10 Nov 2025 | Announcement | Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |